Claude designed protein binders against scorpion neurotoxins
Summary
Anthropic reports Claude designed de novo protein minibinders targeting five scorpion neurotoxins. The campaign generated 318,484 designs, with 211 advanced to testing and 17 meeting the binder criteria, validated by Adaptyv Bio and Twist Bioscience. While the results show promise for accelerated early-stage discovery, the work did not include in vitro neutralization or in vivo efficacy testing, and the team emphasizes safety, affordability, and translational challenges before any therapeutic use.